8-K filed Jun 9, 2026 at 16:05 ET
Arcutis Biotherapeutics filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where all three proposals were approved, including the election of three Class III directors, ratification of Ernst & Young as independent auditor, and non-binding advisory approval of executive compensation. Separately, the Board approved an amended and restated Non-Employee Director Compensation Program, effective June 5, 2026, which sets annual cash retainers (e.g., $50,000 base for non-employee directors) and equity awards (initial option up to $350,000 grant date fair value, annual awards of ~$350,000 split 65% options / 35% RSUs). This is a routine governance filing with no material financial impact.